Scientists Just Cracked the ‘Undruggable’ Cancer Gene That Drives 92% of Pancreatic Tumors — Dallas’s Cancer Centers Are Ready to Deploy It

One of the most celebrated — and humbling — chapters in modern oncology has been the four-decade quest to inhibit KRAS, the gene mutated in 92% of pancreatic cancer cases, approximately 35% of lung cancers, and roughly 45% of colorectal cancers. KRAS was identified as a cancer driver in the early 1980s. For 40 years, attempts to develop drugs that block its protein product failed — the KRAS protein lacks the obvious hydrophobic pockets that most small-molecule drugs require to bind. Researchers called it "undruggable." It became, in the lexicon of oncology, shorthand for intractable biological barriers that defined the limits of targeted therapy.

At the American Society of Clinical Oncology annual meeting in Chicago on May 31, 2026, Revolution Medicines presented Phase 3 RASolute 302 trial data that may formally close that chapter. Daraxonrasib — a pan-RAS inhibitor — nearly doubled overall survival in metastatic pancreatic cancer patients who had already received prior treatment: median overall survival extended from 6.7 months to 13.2 months. The risk of death was reduced by 60% compared to standard chemotherapy. One-third of patients experienced at least a 20% reduction in tumor burden. For a cancer with a 5-year survival rate in metastatic disease of approximately 3%, these numbers are not merely statistically significant — they are clinically transformative.

The Molecular Science: How Daraxonrasib Does What 40 Years of Research Couldn't

The breakthrough came from a fundamental reconceptualization of how to attack RAS proteins. Rather than attempting to bind the active site of the protein — where the structural features required for conventional drug binding are absent — daraxonrasib belongs to a new class of pan-RAS inhibitors that target the protein's interaction with its upstream activators. By disrupting how RAS gets switched "on" rather than trying to block what the "on" state does, the drug circumvents the binding challenge that defeated earlier approaches.

Pan-RAS inhibition — targeting the entire RAS family rather than one specific mutation — is particularly important for pancreatic cancer because the disease involves multiple different KRAS mutations: G12D, G12V, G12R, and others. Earlier RAS-targeted agents, like sotorasib and adagrasib, specifically targeted the KRAS G12C mutation — which is common in lung cancer but rare in pancreatic cancer. Daraxonrasib's pan-RAS activity covers the full spectrum of mutations found in pancreatic tumors, which is why the RASolute 302 Phase 3 trial enrolled 500 participants with solid tumors harboring activating RAS mutations and found broad efficacy across mutation subtypes.

Why This Matters Specifically for Dallas and the Simmons Cancer Center

UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center is among the most advanced oncology institutions in the United States, recently ranked in the top tier by U.S. News & World Report. The center is already at the leading edge of targeted therapy for rare cancers — UT Southwestern became the first institution in Texas and surrounding states to perform whole-liver chemotherapy delivery for metastatic uveal melanoma using the Hepzato Kit, a procedure showing 80% one-year overall survival in the pivotal FOCUS trial. Simmons has the infrastructure, interdisciplinary expertise, and existing RAS research program to rapidly integrate daraxonrasib into clinical practice upon FDA approval — and to offer clinical trial access for patients now.

The broader Dallas–Fort Worth cancer burden makes this breakthrough particularly significant. The Texas Cancer Registry at DSHS identifies pancreatic cancer as one of the state's leading cancer mortality sites. Approximately 5,600 Texans are diagnosed with pancreatic cancer annually, and roughly 80% of those diagnoses involve disease that has already spread beyond the pancreas at the time of detection — because pancreatic cancer produces no symptoms in its early stages, and no population screening program exists. Those are precisely the patients for whom daraxonrasib's second-line efficacy data is most immediately relevant.

The Cancer Statistics 2026 Context: Progress Is Real — and Threatened

Daraxonrasib arrives at a moment the American Cancer Society's Cancer Statistics 2026 report describes as historic: the five-year relative survival rate for all cancers has reached 70%, up from 49% in the mid-1970s. Since the cancer death rate's peak in 1991, it has declined by 34% — approximately 4.8 million deaths prevented. The gains come disproportionately from targeted therapies and immunotherapies that operate on the same molecular precision principle as daraxonrasib: identifying a specific biological driver and blocking it, rather than deploying chemotherapy's non-selective cell-killing approach.

"Research breakthroughs are redefining what's possible for cancer patients and survivors," said Robert Stone, City of Hope CEO, summarizing the 2026 science landscape. City of Hope's experts predict that AI-powered biomarker matching tools will improve clinical trial enrollment rates by up to 26% in 2026, accelerating the translation of discoveries like daraxonrasib from laboratory to patient. For the pancreatic cancer patients in Dallas who have run out of standard options, those tools and that drug may represent the difference between a 6.7-month prognosis and a 13.2-month prognosis — and in the years ahead, potentially much more as combination therapy strategies are explored. Dallas's world-class cancer infrastructure puts its patients in the best possible position to access what comes next.